These problems highlight the need for improvements in the understanding of ERα-positive breast cancer, to develop additional markers that will identify those patients who will respond to hormone therapies, for developing new therapies for ERα-positive patients who do not respond to current endocrine therapies and for identifying new agents to treat patients with ERα-negative disease. Here, ESR1 is linked to breast cancer.